[Hepatic tolerance of aceclofenac]. / Tolerancia hepática del aceclofenac.

NSAID's are largely used drugs. Among the reported side effects of this type of drugs is liver damage. 73 patients suffering from diverse rheumatological pathologies (arthrosis 46.6%, rotators 9.68%, rheumatoid arthritis 21.92%, lumbalgia 5.48%, other diagnosis 6.85%) were evaluated. Aceclofenac (AC) 100 mg. dose every 12 hours was administered. A Transaminase value determination was taken both at the beginning and end of medication for each patient. Average age of patients was 52.71 years, 78% being female. Treatment was administered as follows, 42.47% of the patients received a 60 days treatment, 28.8% a 45 days treatment, 23.3% a 30 days treatment and 5.47% received a 15 days treatment. Reported mean GOT value at the beginning was 16.6 U, at the end 17.01 U. GPT initial value was 15.84 U and final 16.53 U. A GOT increase, 20 U to 50 was observed in a single patient. GPT was also increased from 32 U to 47 U in one case. Results led us to a no liver damage report of the NSAID's AC in these group of patients.

[Percutaneous liver biopsy in outpatients]. / Biopsia hepática percutánea en pacientes ambulatorios.

We studied prospectively 44 patients with diffuse liver disease. We performed percutaneous liver biopsy in these outpatients. They were required to be in absolute response during the following 4-6 hours after the biopsy was completed. After that period, they could go home and have a relative rest for the remnant day. These patients were followed by clinical evaluation and by real time abdominal ultrasound. We found some complications: Transitory arterial hypotension, pain in the site of puncture, hepatic hematomas. Only one of the patients with hematomas required hospitalization during 24 hours. The mortality was 0%. According to our experience, the hepatic biopsy is a procedure that can be performed in outpatients with a wide margin of security. An important point of view to consider is the economic advantage since it means a decrease in costs by each hepatic biopsy accomplished considering the cost/day of hospitalization.